Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Could FcRn blockers become the next biologics blockbuster class after interleukin inhibitors and JAKs? A new frontier is emerging in the world of biologic therapies. After years of dominance by interleukin inhibitors… byVenkateshOctober 25, 2025